Download Free Overcoming Physiologic Barriers To Treatments For Hematologic Malignancies By Molecularly Targeting The Tumor Microenvironment Book in PDF and EPUB Free Download. You can read online Overcoming Physiologic Barriers To Treatments For Hematologic Malignancies By Molecularly Targeting The Tumor Microenvironment and write the review.

Hematologic malignancies (HMs) represent a group of hematologic cancers originating from bone marrow or lymphoid organs. Currently, leukaemia, lymphoma, and multiple myeloma are the most common HMs. Conventional treatments for HMs include bone marrow transplantation, radiotherapy, chemotherapy, and immunotherapy. Despite the significant achievements obtained over the past decade in the drug therapy of HMs, tumor metastasis and relapse in patients often occurred after an initial response, indicating the generation of drug resistance to current therapies. Moreover, many clinically used therapeutic drugs are often associated with dose-related side effects and a lack of specificity to tumor tissues. The tumor microenvironment (TME) in HMs consists of a complicated network of cellular interactions and signaling cross-talking within the bone marrow cavity, and it plays an essential role in the progression and metastasis of HM. Furthermore, the TME in HMs has formed physiologic barriers such as immunosuppressive microenvironment, upregulated anti-apoptotic system, drug resistance, etc. to facilitate drug resistance and relapse of HMs. It has become widely accepted that effective treatment against HMs may require targeting both the cancer cell and TME.
Sarcoma Oncology: A Multidisciplinary Approach is a comprehensive textbook that addresses the entire spectrum of the subject from epidemiology to laboratory research in the biology of sarcomas. Chapters contributed by an international group of highly regarded specialists cover the epidemiology and pathology of sarcomas; diagnostic imaging and biopsy techniques; staging and prognosis: surgery of sarcomas in extremity soft tissue, abdominal wall and trunk, and skeletal bone; hyperthermia in sarcoma treatment; isolated limb perfusion; surgery for metastases; reconstructive surgery; radiation therapy; systemic chemotherapy; multidisciplinary care; treatment-induced sarcoma; pain management in sarcoma; and basic research including molecular biology and mouse models.
Since the invention of nanomedicine decades ago, considerable progresses have been made, especially with cancer as a target. Nanoparticles have been proven to be powerful imaging tools or potent agents for cancer diagnosis, treatment and prevention. Active research spread from fundamental research to clinical investigations. This topic intends to cover several important aspects in this field including nanocarrier development, gene delivery, intrinsically active nanoparticles, tumor microenvironment, immunology, and toxicity.
Significance of Stem Cells to Tumor Development Cancer stem cells remain a controversial topic and the criteria that define cancer stem cells are continuing to evolve. A recent surge in stem cell research has ignited a field of discovery into many human diseases including diabetes, neuropathologies, and cancer. By replacing specific differentiated cells that have either been lost or died, stem cell therapy proves to be a very promising approach to the treatment of many debilitating diseases. Though stem cells may provide therapeutic benefit under certain conditions, they are also often implicated in the initiation, progression, and therapeutic resistance of malignant disease. This first edition of Stem Cells and Cancer is intended to give a current perspective on the role of stem cells in cancer and strategies for novel therapies directed toward tumor stem cells. The current cancer stem cell hypothesis is presented in several chapters with distinctions made between the hierarchical and stochastic models of tumor cell development. "Stemness," self-renewal, pluripotency, clonality, and tumorigenicity are important concepts applied towards defining cancer stem cells. Signaling pathways such as Wnt, Sonic Hedgehog, Notch, and Bmi-1 that are involved in differentiation, proliferation, and survival are implicated in the malignant process. Additional chapters address the identification of cancer stem cell populations through the evaluation of molecular markers such as CD133, CD44, and CD24, for example, or by Hoescht dye exclusion to recognize ‘side populations.’ Mesenchymal and hematopoietic stem cells are described as well as mouse models that are employed to elucidate the properties and functionality of stem cells in cancer and the stem cell niche. This book encompasses a wide variety of human cancers that include but are not limited to leukemia, gliomas, breast, and prostate cancers. Resistance to conventional therapies, genetic versus epigenetic changes that affect therapeutic response and strategies to prevent disease recurrence are challenges have been incorporated into this volume. Stem Cells and Cancer represents a compendium of cutting edge research by experts in the field and will be instrumental in the study of this intriguing line of investigation for many years to come. Rebecca Bagley is a senior scientist at Genzyme Corporation and has worked in the biotechnology industry for 20 years with degrees in biology from Wellesley College and Harvard University. Her expertise in drug development spans a wide range of approaches including immunotherapies, gene and protein therapies, and small molecule delivery with publications in journals such as Molecular Cancer Therapeutics, Cancer Research, and Microvascular Research . Her current research focuses on stem cells, tumor vasculature, and target validation. Dr. Beverly A. Teicher is Vice President of Oncology Research at Genzyme Corporation. Dr. Teicher completed a PhD in Bioorganic Chemistry at the Johns Hopkins University and postdoctoral training at Yale University School of Medicine. Dr. Teicher joined Dana-Farber Cancer Institute as an Assistant Professor of Pathology and rose to Associate Professor of Medicine and Radiation Therapy, Harvard Medical School at Dana-Farber Cancer Institute and Joint Center for Radiation Therapy. Dr. Teicher is an active member of the international scientific community having authored or co-authored more than 400 scientific publications. She has edited eight books, is senior editor for the journal Clinical Cancer Research and is series editor for the Cancer Drug Discovery and Development book series.
This book describes barriers from the macro to the nanoscale, starting with endothelial and mucosal barriers, and ending with cellular organelles. Experimental approaches to track nanoparticles in vitro and in vivo are presented, as well as the ability to tailor-make nanoparticles for specific functions. Several model types of nanoparticles are presented, as well the impact of particle attributes on biological transport.
This title demonstrates how advanced formulation designs and delivery technologies can be used to improve drug efficacy and treatment outcomes in particular therapeutic categories or disease states. It discusses nanoparticle systems for cancer treatments, and also presents cutting edge immono-regulation agents for transplantation and the local targ
"This book is essential when designing, developing and studying biomedical materials. provides an excellent review-from a patient, disease, and even genetic point of view-of materials engineering for the biomedical field. This well presented book strongly insists on how the materials can influence patients' needs, the ultimate drive for biomedic
Numerous developments in molecular biology have led to an explosive growth in the knowledge underlying mechanisms of carcinogenesis, cell signalling, tumor progression and development of metastasis. However, cure of cancer is still hampered by the inherited capacity of tumors to become resistant to standard therapies, to metastasize from their initial location and to proliferate in other tissue compartments. Radiotherapy is one of the main treatment modalities to achieve locoregional tumor control. However, the treatment of distant metastases further remains to be a challenge. In this special topic we are interested to elucidate immunological aspects which are initiated and affected by radiotherapy. We also aim to describe the development of innovative immunological strategies from a preclinical stage to clinical application which could be combined with standard radiotherapeutic approaches. A special interest will also deal with the effects of radiotherapy on tumor initiating cells as well as on the tumor microenvironment. Last but not least the effects of different irradiation sources and qualities such as photones, protones and heavy ions will be analyzed with respect to immunological outcome.
Today we find the applications of nanotechnology in all spheres of life. Nanotechnology: Therapeutic, Nutraceutical and Cosmetic Advances discusses recent advances in the field, particularly with therapeutics, nutraceuticals and cosmetic sciences. Therapeutics is an area which has perhaps benefitted the most, although nanoscience and technology have quietly entered the realms of food science and are playing pivotal roles in the efficient utilization of nutraceuticals. Finally, even before therapeutics came cosmetics and companies started marketing unique products embedding the beneficial and advanced properties enabled by the use of nanostructures. This book highlights trends and applications of this wonderful new technology.
The immune system harbors great potential for controlling and eliminating tumors. Recent developments in the field of immuno-oncology has led to unprecedented clinical benefits for a broad spectrum of solid tumors. However, immunotherapy (IT) approaches currently have several limitations including (i) low response rate; (ii) development of resistance and (iii) causing severe immune-related adverse effects (IrAEs), which underline the importance of adequate patient selection. Importantly, IT holds promising synergistic potential when combined with standard-of-care chemotherapy, radiotherapy (RT) and anti-angiogenic therapy (AAT) as part of multi-modal oncologic treatment regimes. Published data suggest that there are potential synergy between RT and AAT, which ultimately could help potentiate the response to IT. However, the complex interactions between RT and IT and/or AAT remain poorly understood. Many research questions including optimal timing, scheduling and dosing, as well as patient selection and side effects of combined therapy approaches, remain to be addressed. This Research Topic aims to give a comprehensive overview of the current field with particular emphasis on the future outlook of RT and AAT as complementary approaches to improve IT in solid tumors.